Investment Insights: Israeli microbiome firm BiomX set for €24 million capital

Investment Insights: Israeli microbiome firm BiomX set for €24 million capital

Paris-based Seventure Partners are among several venture funds to put a total of €24 million into Israeli microbiome therapeutics company BiomX (formerly called MBCure).

Seventure said €3 million of the total was invested into BiomX through its Health for Life Capital vehicle, as part of a wider global syndicate which includes corporate venture funds Takeda Ventures and Johnson and Johnson Development Corporation, Venture Investor Orbimed, Korean fund manager Mirae Asset Global Investments, and SBI, a subsidiary of Softbank of Japan, as well as European family office investors.

BiomX works on the development of novel therapeutics for human diseases linked to the microbiome. Its initial product candidates are based on bacteriophages (viruses which target and kill specific species or strains of bacteria), however the firm also uses unique technologies to identify microbiome targets for key diseases.

Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners and founder of Health for Life Capital, noted that the microbiome field is complex with multiple approaches having synergistic roles in healthcare.

“BiomX’s approach using bacteriophage seeks to harness natural mechanisms to restore a healthy microbiome balance to the gut,” she said – adding that investment in BiomX ‘rounds out’ its microbiome portfolio, which already includes Enterome (microbiome modulator drugs, diagnostics and companion diagnostics), LNC (drug-probiotic and nutrition microbiome-modulator products), Maat Pharma (autologous microbiome transplant), TargEDys (bacteria for regulation of appetite), Eligo Bioscience (phage-derived highly-specific antibiotics) and Vedanta (drug-probiotic).

The €24 million investment will be used for further developing therapeutic candidates and obtaining clinical proof of concept that will allow BiomX to develop further IP and position itself as a major player in developing therapeutics.

“We anticipate making additional investments from the Health for Life Capital in the coming months,” added Cremoux.

Related News

Could probiotics restore microbiome imbalance linked to autoimmune disorder?

Could probiotics restore microbiome imbalance linked to autoimmune disorder?

©iStock-frentusha

Nestlé-backed study links probiotic strain and depression

The initiative hopes to give entrepreneurs a leg up in a competitive market boosting their chances with a tie-up with DSM. ©iStock/DigitalStorm

Dragons Den event for nutrition industry a "win-win" for all concerned

Europe’s nutrition ‘Silicon Valley’ propelling a new generation of startups

Europe’s nutrition ‘Silicon Valley’ propelling a new generation of startups

Log-in to #PNEvent17 for free on 26 January. ©iStock/digitalgenetics

I-nutrition: This time it’s personal

©iStock/violka8

Asian VC invests €33m in Indian botanicals specialist; acquisitions targeted

©iStock

EU launches huge start-up scheme; €1.6bn funding boost potential

Map My Gut offers paying customers specialist gut microbiome analysis and personalised nutrition advice based on metagenome testing. ©iStock/TLFurrer

'In five years this will be routine': Map My Gut start-up offers personalised microbiome advice

©iStock/BrianAJackson

Top 10 nutrition start-ups

Glanbia Performance Nutrition EBITA was up 35% in the first half of 2016 when compared to the same period in 2015.

Glanbia Performance Nutrition drives Glanbia 2016 half year results